InVivo Therapeutics (NVIV) issues a PR saying its degradable polymer scaffold trial will "be ready to enroll patients in Q1 2014."
The company also says it "will submit a filing containing proposed changes to its FDA-approved protocol and supporting documents within the next ten days."
NVIV thinks the changes, if approved, would "accelerate the progress of [the] trial by eliminating barriers to enrollment and by expanding the number of sites from at least three to as many as six."
Additionally, the company says it has temporarily suspended "most work" on hydrogel in order to focus on scaffold manufacturing. NVIV says it has "entered into discussions with a number of prospective corporate partners based on this new business model." (PR)